all report title image

HYPERHIDROSIS TREATMENT MARKET ANALYSIS

Hyperhidrosis Treatment Market, by Drug Class (Anticholinergics and Antiperspirants), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) –Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Nov 2024
  • Code : CMI2800
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Challenges And Opportunities

Global Hyperhidrosis Treatment Market Restraints

Side effects of drugs may hamper the global hyperhidrosis treatment market growth. For instance, drystol is a topical treatment of hyperhidrosis, which includes side effects such as mild itching, burning, allergic reactions, severe burning, dizziness, and swelling on the applied area. Hence, such side effects of drugs may obstruct the global hyperhidrosis treatment market growth.

Global Hyperhidrosis Treatment Market Drivers

Key players are focused on developing new products for the treatment of hyperhidrosis, which is expected to boost the global hyperhidrosis treatment market growth. For instance, in October 2018, Dermira Inc., launched Qbrexa cloth for the treatment of primary axillary hyperhidrosis. It contains anti-cholinergic drug, glycopyrronium and is designed for adults as well as pediatrics (aged 9 years and above). It received the U.S. Food & Drug Administration approval in June, 2018. Furthermore, in December 2016, GlaxoSmithKline completed its phase II clinical trials study of Umeclidinium for the treatment of hyperhidrosis. The purpose of the study was to evaluate the efficacy, pharmacokinetics, and tolerability of the drug in the patients with primary axillary hyperhidrosis. The study revealed that on the 15th day of the treatment, minimum 50% of sweat reduction was observed in around in seven patients. Hence, such developments are expected to fuel growth of global hyperhidrosis treatment market over the forecast period. Adoption of strategies such as mergers, acquisitions, and collaborations by key players is expected to drive the global hyperhidrosis market growth. For instance, in April 2015, Brickell Biotech Inc., a clinical-stage pharmaceutical company entered into an agreement with Kaken Pharmaceutical Co., Ltd., a pharmaceutical company for the development of BBI-4000. It is a topical anticholinergic used for the treatment of hyperhidrosis. Hence, such agreements are expected to propel the global hyperhidrosis market growth.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.